Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
omalizumab (xolair) (1 trial)
monophosphoryl lipid a (1 trial)
ny-eso-1 peptides (1 trial)
Asthma (Phase 4)
Melanoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (3 total)